A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of patients who achieve a clinical benefit response including CR, CRp, PR and major HI
2 years
Yes
United States: Food and Drug Administration
CYC682-11
NCT01211457
June 2010
June 2012
Name | Location |
---|---|
MD Anderson Cancer Center | Houston, Texas 77030-4096 |
Roswell Park Cancer Institute | Buffalo, New York 14263 |
Rush University Medical Center | Chicago, Illinois 60612-3824 |